Activity of purine analogs against Leishmania donovani in vivo.
The dose of orally administered 9-deazainosine calculated to suppress 50% of Leishmania donovani amastigotes in hamster livers was 19 mg/kg (body weight) per day; 96 to 99% of Leishmania organisms were eliminated from the liver and spleen of squirrel monkeys by 50 mg/kg per day. Because these activities were greater than that of the experimental clinical agent allopurinol and comparable to that of the classical agent parenteral pentavalent antimony, 9-deazainosine should be considered for clinical development for visceral leishmaniasis.
D000284:Administration, Oral; D000493:Allopurinol / Q000008:administration & dosage / Q000494:pharmacology; D000818:Animals; D006224:Cricetinae; D005573:Formycins / Q000008:administration & dosage / Q000494:pharmacology; D006151:Guanosine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology; D007273:Injections, Intramuscular; D007288:Inosine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D007893:Leishmania donovani / Q000187:drug effects*; D007898:Leishmaniasis, Visceral / Q000188:drug therapy* / Q000469:parasitology; D008099:Liver / Q000469:parasitology; D008297:Male; D008536:Meglumine / Q000008:administration & dosage / Q000494:pharmacology; D000077485:Meglumine Antimoniate; D008647:Mesocricetus; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000494:pharmacology; D012453:Saimiri; D013154:Spleen / Q000469:parasitology
D005573:Formycins; D009942:Organometallic Compounds; D006151:Guanosine; C010568:3-deazaguanosine; D007288:Inosine; D000493:Allopurinol; D008536:Meglumine; D000077485:Meglumine Antimoniate; C048839:9-deazainosine